Research Progress of Adverse Events Related to PD-1/PD-L1 Inhibitors Based Combination Therapy
The development of immune checkpoint inhibitors (ICIs) has significantly improved the prognosis of cancer patients, but a large population of patients are still ineffective to ICIs treatment or develop aquired drug resistance. In order to improve the clinical benefits, a number of studies on ICIs ba...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2021-07-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.26 |
| _version_ | 1818652785987551232 |
|---|---|
| author | Xiaoyu GUO Ti WEN Xiujuan QU |
| author_facet | Xiaoyu GUO Ti WEN Xiujuan QU |
| author_sort | Xiaoyu GUO |
| collection | DOAJ |
| description | The development of immune checkpoint inhibitors (ICIs) has significantly improved the prognosis of cancer patients, but a large population of patients are still ineffective to ICIs treatment or develop aquired drug resistance. In order to improve the clinical benefits, a number of studies on ICIs based combination therapy have been actively explored, and have achieved satisfactory results. With the application of ICIs based combination therapy in clinical practice, increasing attention has been paid to the safety of combination therapy and the management of treatment-related adverse events. In this review, the characteristics of adverse events related to ICIs based combination therapies, especially programmed cell death protein 1/protein ligand 1 (PD-1/PD-L1) inhibitors are discussed, in order to provide profound thoughts for toxicity evaluation and individualized treatment decision in future clinical practice. |
| first_indexed | 2024-12-17T02:27:32Z |
| format | Article |
| id | doaj.art-659504b088444d7884c5f2d7348817ed |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-12-17T02:27:32Z |
| publishDate | 2021-07-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-659504b088444d7884c5f2d7348817ed2022-12-21T22:07:04ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872021-07-0124751351810.3779/j.issn.1009-3419.2021.101.26Research Progress of Adverse Events Related to PD-1/PD-L1 Inhibitors
Based Combination TherapyXiaoyu GUO0Ti WEN1Xiujuan QU2Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, ChinaDepartment of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, ChinaDepartment of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, ChinaThe development of immune checkpoint inhibitors (ICIs) has significantly improved the prognosis of cancer patients, but a large population of patients are still ineffective to ICIs treatment or develop aquired drug resistance. In order to improve the clinical benefits, a number of studies on ICIs based combination therapy have been actively explored, and have achieved satisfactory results. With the application of ICIs based combination therapy in clinical practice, increasing attention has been paid to the safety of combination therapy and the management of treatment-related adverse events. In this review, the characteristics of adverse events related to ICIs based combination therapies, especially programmed cell death protein 1/protein ligand 1 (PD-1/PD-L1) inhibitors are discussed, in order to provide profound thoughts for toxicity evaluation and individualized treatment decision in future clinical practice.http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.26tumorpd-1/pd-l1 inhibitorscombination therapyadverse events |
| spellingShingle | Xiaoyu GUO Ti WEN Xiujuan QU Research Progress of Adverse Events Related to PD-1/PD-L1 Inhibitors Based Combination Therapy Chinese Journal of Lung Cancer tumor pd-1/pd-l1 inhibitors combination therapy adverse events |
| title | Research Progress of Adverse Events Related to PD-1/PD-L1 Inhibitors
Based Combination Therapy |
| title_full | Research Progress of Adverse Events Related to PD-1/PD-L1 Inhibitors
Based Combination Therapy |
| title_fullStr | Research Progress of Adverse Events Related to PD-1/PD-L1 Inhibitors
Based Combination Therapy |
| title_full_unstemmed | Research Progress of Adverse Events Related to PD-1/PD-L1 Inhibitors
Based Combination Therapy |
| title_short | Research Progress of Adverse Events Related to PD-1/PD-L1 Inhibitors
Based Combination Therapy |
| title_sort | research progress of adverse events related to pd 1 pd l1 inhibitors
based combination therapy |
| topic | tumor pd-1/pd-l1 inhibitors combination therapy adverse events |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.26 |
| work_keys_str_mv | AT xiaoyuguo researchprogressofadverseeventsrelatedtopd1pdl1inhibitorsbasedcombinationtherapy AT tiwen researchprogressofadverseeventsrelatedtopd1pdl1inhibitorsbasedcombinationtherapy AT xiujuanqu researchprogressofadverseeventsrelatedtopd1pdl1inhibitorsbasedcombinationtherapy |